DE19951671A1 - 2-(4,6-Dimethyl-pyrimidin-2-yloxy)-3-(2-(3,4-dimethoxyphenyl)ethoxy)-3,3-diphenylpropionssäure-Natriumsalz und seine Verwendung als Endothelinantagonist - Google Patents

2-(4,6-Dimethyl-pyrimidin-2-yloxy)-3-(2-(3,4-dimethoxyphenyl)ethoxy)-3,3-diphenylpropionssäure-Natriumsalz und seine Verwendung als Endothelinantagonist

Info

Publication number
DE19951671A1
DE19951671A1 DE19951671A DE19951671A DE19951671A1 DE 19951671 A1 DE19951671 A1 DE 19951671A1 DE 19951671 A DE19951671 A DE 19951671A DE 19951671 A DE19951671 A DE 19951671A DE 19951671 A1 DE19951671 A1 DE 19951671A1
Authority
DE
Germany
Prior art keywords
dimethoxyphenyl
ethoxy
compound
yloxy
sodium salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE19951671A
Other languages
German (de)
English (en)
Inventor
Rolf Jansen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott GmbH and Co KG
Original Assignee
BASF SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BASF SE filed Critical BASF SE
Priority to DE19951671A priority Critical patent/DE19951671A1/de
Priority to BR0015112-2A priority patent/BR0015112A/pt
Priority to PCT/EP2000/010202 priority patent/WO2001030767A1/fr
Priority to CA002389012A priority patent/CA2389012A1/fr
Priority to MXPA02004071A priority patent/MXPA02004071A/es
Priority to IL14931200A priority patent/IL149312A0/xx
Priority to JP2001533121A priority patent/JP2003512460A/ja
Priority to SK596-2002A priority patent/SK5962002A3/sk
Priority to EP00974404A priority patent/EP1228047A1/fr
Priority to CZ20021485A priority patent/CZ20021485A3/cs
Priority to KR1020027005457A priority patent/KR20020047301A/ko
Priority to CN00814871A priority patent/CN1384822A/zh
Priority to HU0203476A priority patent/HUP0203476A3/hu
Priority to AU12727/01A priority patent/AU1272701A/en
Priority to TR2002/01169T priority patent/TR200201169T2/xx
Publication of DE19951671A1 publication Critical patent/DE19951671A1/de
Priority to NO20021986A priority patent/NO20021986D0/no
Priority to BG106700A priority patent/BG106700A/xx
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE19951671A 1999-10-27 1999-10-27 2-(4,6-Dimethyl-pyrimidin-2-yloxy)-3-(2-(3,4-dimethoxyphenyl)ethoxy)-3,3-diphenylpropionssäure-Natriumsalz und seine Verwendung als Endothelinantagonist Withdrawn DE19951671A1 (de)

Priority Applications (17)

Application Number Priority Date Filing Date Title
DE19951671A DE19951671A1 (de) 1999-10-27 1999-10-27 2-(4,6-Dimethyl-pyrimidin-2-yloxy)-3-(2-(3,4-dimethoxyphenyl)ethoxy)-3,3-diphenylpropionssäure-Natriumsalz und seine Verwendung als Endothelinantagonist
CZ20021485A CZ20021485A3 (cs) 1999-10-27 2000-10-17 2-(4,6-Dimethylpyrimidinyl-2-oxy)-3-[2-(3,4-dimethoxyfenyl)ethoxy]-3,3-difenylpropionát sodný a jeho použití jako endothelinového antagonistu
KR1020027005457A KR20020047301A (ko) 1999-10-27 2000-10-17 소듐2-(4,6-디메틸-피리미딘-2-일옥시)-3-(2-(3,4-디메톡시페닐)에톡시)-3,3-디페닐프로피오네이트 및 엔도텔린길항제로서의 그의 용도
CA002389012A CA2389012A1 (fr) 1999-10-27 2000-10-17 Sel de potassium d'acide 2-(4,6-dimethyl-pyrimidin-2-yloxy)-3-(2-(3,4-dimethoxyphenyl)ethoxy)-3,3-diphenylpropionique et son utilisation comme antagoniste endothelial
MXPA02004071A MXPA02004071A (es) 1999-10-27 2000-10-17 2-(4,6-dimetil -pirimidin-2-iloxi) -3-(2-(3,4 -dimetoxifenil) etoxi) -3, 3-difenil propionato de sodio y su uso como antagonista de endotelina.
IL14931200A IL149312A0 (en) 1999-10-27 2000-10-17 Sodium 2-(4,6-dimethyl-pyrimidin-2-yloxy)-3-(2-(3,4-dimethoxyphenyl)ethoxy)-3,3-diphenylpropionate and use thereof as endothelin antagonist
JP2001533121A JP2003512460A (ja) 1999-10-27 2000-10-17 ２−（４，６−ジメチル−ピリミジン−２−イルオキシ）−３−（２−（３，４−ジメトキシフェニル）エトキシ）−３，３−ジフェニルプロピオン酸−ナトリウム塩及びエンドセリンアンタゴニストとしてのその使用
SK596-2002A SK5962002A3 (en) 1999-10-27 2000-10-17 Sodium 2-(4,6-dimethyl-pyrimidin-2-yloxy)-3-(2-(3,4- dimethoxyphenyl)ethoxy)-3,3-diphenylpropionate and use thereof as endothelin antagonist
EP00974404A EP1228047A1 (fr) 1999-10-27 2000-10-17 Sel de potassium d'acide 2-(4,6-dimethyl-pyrimidin-2-yloxy)-3-(2-(3,4-dimethoxyphenyl)ethoxy)-3,3-diphenylpropionique et son utilisation comme antagoniste endothelial
BR0015112-2A BR0015112A (pt) 1999-10-27 2000-10-17 Composto, método para uso do mesmo, e, produto farmacêutico
PCT/EP2000/010202 WO2001030767A1 (fr) 1999-10-27 2000-10-17 Sel de potassium d'acide 2-(4,6-dimethyl-pyrimidin-2-yloxy)-3-(2-(3,4-dimethoxyphenyl)ethoxy)-3,3-diphenylpropionique et son utilisation comme antagoniste endothelial
CN00814871A CN1384822A (zh) 1999-10-27 2000-10-17 2－(4,6－二甲基嘧啶基－2－氧基)－3－[2－(3,4－二甲氧基苯基)乙氧基]－3,3－二苯基丙酸钠及其作为内皮素拮抗剂的用途
HU0203476A HUP0203476A3 (en) 1999-10-27 2000-10-17 Sodium 2-(4,6-dimethyl-pyrimidin-2-yloxy)-3-(2-(3,4-dimethoxyphenyl)ethoxy)-3,3-diphenylpropionate, use thereof and pharmaceutical composition containing the same
AU12727/01A AU1272701A (en) 1999-10-27 2000-10-17 Sodium 2-(4,6-dimethyl-pyrimidin-2-yloxy)-3-(2-(3,4- dimethoxyphenyl)ethoxy)-3,3-diphenylpropionate and use thereof as endothelin antagonist
TR2002/01169T TR200201169T2 (tr) 1999-10-27 2000-10-17 2-(4,6-Dimetilpirimidinil-2-oksi)-3- [2-(3,4-dimetoksifenil)etoksi]-3,3-difenilpropiyonat ve endotelin antagonist olarak kullanılması
NO20021986A NO20021986D0 (no) 1999-10-27 2002-04-26 Natrium-2-(4,6-dimetyl-pyrimidin-2-yloksy)-3-(2-(3,4- dimetoksyfenyl)etoksy)-3,3-difenylpropionat og anvendelse deravsom endothelin-antagonist
BG106700A BG106700A (en) 1999-10-27 2002-05-14 Sodium 2-(4,6-dimethylpyrimidin-2-yloxy)-3-(2-(3,4-dimethoxyphenyl) ethoxy-3,3-diphenylpropionate and use thereof as endothelin antagonist

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19951671A DE19951671A1 (de) 1999-10-27 1999-10-27 2-(4,6-Dimethyl-pyrimidin-2-yloxy)-3-(2-(3,4-dimethoxyphenyl)ethoxy)-3,3-diphenylpropionssäure-Natriumsalz und seine Verwendung als Endothelinantagonist

Publications (1)

Publication Number Publication Date
DE19951671A1 true DE19951671A1 (de) 2001-05-03

Family

ID=7927001

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19951671A Withdrawn DE19951671A1 (de) 1999-10-27 1999-10-27 2-(4,6-Dimethyl-pyrimidin-2-yloxy)-3-(2-(3,4-dimethoxyphenyl)ethoxy)-3,3-diphenylpropionssäure-Natriumsalz und seine Verwendung als Endothelinantagonist

Country Status (17)

Country Link
EP (1) EP1228047A1 (fr)
JP (1) JP2003512460A (fr)
KR (1) KR20020047301A (fr)
CN (1) CN1384822A (fr)
AU (1) AU1272701A (fr)
BG (1) BG106700A (fr)
BR (1) BR0015112A (fr)
CA (1) CA2389012A1 (fr)
CZ (1) CZ20021485A3 (fr)
DE (1) DE19951671A1 (fr)
HU (1) HUP0203476A3 (fr)
IL (1) IL149312A0 (fr)
MX (1) MXPA02004071A (fr)
NO (1) NO20021986D0 (fr)
SK (1) SK5962002A3 (fr)
TR (1) TR200201169T2 (fr)
WO (1) WO2001030767A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2489659B1 (fr) 2004-06-24 2017-12-13 Vertex Pharmaceuticals Incorporated Modulateurs de transporteurs de cassette de liaison a l´ATP

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19636046A1 (de) * 1996-09-05 1998-03-12 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶A¶/ET¶B¶-Rezeptorantagonisten

Also Published As

Publication number Publication date
EP1228047A1 (fr) 2002-08-07
BR0015112A (pt) 2002-10-29
NO20021986L (no) 2002-04-26
CA2389012A1 (fr) 2001-05-03
BG106700A (en) 2003-02-28
CN1384822A (zh) 2002-12-11
HUP0203476A3 (en) 2003-07-28
CZ20021485A3 (cs) 2003-06-18
KR20020047301A (ko) 2002-06-21
MXPA02004071A (es) 2002-10-11
SK5962002A3 (en) 2002-09-10
JP2003512460A (ja) 2003-04-02
HUP0203476A2 (en) 2003-05-28
TR200201169T2 (tr) 2002-09-23
NO20021986D0 (no) 2002-04-26
WO2001030767A1 (fr) 2001-05-03
AU1272701A (en) 2001-05-08
IL149312A0 (en) 2002-11-10

Similar Documents

Publication Publication Date Title
DE2711451C2 (fr)
DE2351412C2 (de) 2,2-Disubstituierte 1-Oxo-5-indanyloxy-carbonsäuren, Verfahren zu deren Herstellung und Spaltung racemischer Gemische, sowie diese enthaltende Arzneimittel
DE2112026B2 (de) 3-Phenyl-H2-[pyrroUdinyl-(l)] äthylamino)-3,4dihydroisochinolin, seiner Herstellung und die es enthaltenden medizinischen Zusammensetzungen
EP0161599A2 (fr) Dérivés de benzazépine, médicaments contenant les composés et procédé pour leur préparation
DE10129832A1 (de) Deuterierte N- und alpha-substituierte Diphenylalkoxyessigsäureaminoalkylester sowie diese Verbindungen enthaltende Arzneimittel
EP0040761A1 (fr) 2-Nitroimidazoles, leur préparation et leur utilisation ainsi que compositions les contenant
EP0132811A1 (fr) Hydroxyméthyl-4 pyrrolidinones substituées en position 1, procédés pour leur préparation, compositions pharmaceutiques et produits intermédiaires
EP0276804B1 (fr) (Alkyl-3 tert-butyl-5 hydroxy-4 phényl)-5 amino-2 6H-thiadiazines-1,3,4, leur procédé de préparation, médicaments les contenant et leur application
EP0402806B1 (fr) Sels d'addition cristallins céphème-acide et procédé pour leur préparation
EP1317430B1 (fr) Derives de (2-azabicyclo [2.2.1]hept-7-yl)methanol utilises comme angonistes du recepteur de l'acetylcholine nicotinique
DE3139554C2 (fr)
DE19951671A1 (de) 2-(4,6-Dimethyl-pyrimidin-2-yloxy)-3-(2-(3,4-dimethoxyphenyl)ethoxy)-3,3-diphenylpropionssäure-Natriumsalz und seine Verwendung als Endothelinantagonist
CH645540A5 (de) Arzneimittel mit immunstimulierender wirkung, darin enthaltene n-substiuierte aziridin-2-carbonsaeurederivate und verfahren zu ihrer herstellung.
DE2236876C3 (de) N-Substituierte Aminocarbonsäuren und diese Verbindungen enthaltende Arzneimittel
DE69812599T2 (de) Imino-aza-anthracyclonderivate zur behandlung von amyloidosis
DE3045720A1 (de) N-pyrimidinyl-carbaminsaeureester, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
EP0095641B1 (fr) Dérivés de la quinazolinone, leur procédé de préparation et leur utilisation dans des médicaments
EP0442348B1 (fr) Composés d'imidazole, procédé de préparation, médicaments à base de ces composés et quelques intermédiaires
CH675419A5 (fr)
DE1959402A1 (de) Neue 2-(5-Nitro-2-furyl)-4-oxi-thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
DE2004301A1 (de) Phenylserinderivate
DE3107594A1 (de) Neue piperazin-verbindungen, verfahren zu ihrer herstellung und ihre verwendung
EP0498011B1 (fr) Sels de l'acide 2-(2,6-dichloroanilino)-phénylacétique procédé pour leur préparation et leur application comme préparation pharmaceutique pour utilisation topique
DE1443376C3 (de) Verfahren zur Herstellung von 2-Amino-alpha-substituierten Benzylidenaminen, sowie neue 2-Amino-alpha-substituierte Benzylidenamine als solche
DE3105122A1 (de) Neue piperazin-verbindungen, verfahren zu ihrer herstellung und ihre verwendung

Legal Events

Date Code Title Description
8127 New person/name/address of the applicant

Owner name: ABBOTT GMBH & CO. KG, 65205 WIESBADEN, DE

8139 Disposal/non-payment of the annual fee